GlassScriptPhysician profile
Diana Miller
NPI 1407204969
$9,876.59
in general payments reported to CMS, 2019-2025
20 companies · $1,981 in 2025
The $1,981 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $115 · 2020: $191 · 2021: $1,794 · 2022: $1,884 · 2023: $1,891 · 2024: $2,021 · 2025: $1,981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,892.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $4,476.55 | 2020-2025 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $3,126.82 | 2020-2025 | Sunlenca, Biktarvy |
| Janssen Biotech, INC. | $1,126.18 | 2020-2023 | Symtuza |
| Janssen Products, LP | $413.60 | 2019-2021 | |
| Lilly USA, LLC | $136.57 | 2023-2025 | Mounjaro, Zepbound |
| Theratechnologies INC. | $98.56 | 2022-2024 | Egrifta, Trogarzo |
| Abbvie INC. | $97.33 | 2022 | |
| Hologic Sales and Service, LLC | $62.42 | 2025 | Aptima |
| Merck Sharp & Dohme LLC | $57.67 | 2021-2025 | Pifeltro, Vaxneuvance, Gardasil 9 |
| Emd Serono, INC. | $52.90 | 2024-2025 | |
| Novo Nordisk INC | $45.94 | 2024-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $35.60 | 2024-2025 | |
| Exact Sciences Corporation | $23.34 | 2024 | Cologuard Collection Kit |
| Corcept Therapeutics | $21.42 | 2025 | Korlym |
| Sanofi Pasteur INC. | $21.32 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $19.79 | 2023 | Bexsero |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.90 | 2020 | |
| Amarin Pharma, INC. | $15.39 | 2019 | |
| Tolmar, INC. | $14.08 | 2025 | Jatenzo |
| Smith+Nephew, INC. | $13.21 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.